Chair Rodgers Opening Remarks on the Regulation of Diagnostic Tests (3.21.24)

Energy & Commerce GOP
48 followers
Mar 21, 2024
The Committee on Energy and Commerce is the oldest standing legislative committee (established 1795) in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee. The Energy and Commerce Committee is at the forefront of all issues and policies powering America’s economy, including our global competitive edge in energy, technology, and health care. The committee is led by E&C Chair Cathy McMorris Rodgers (R-WA) and E&C Ranking Member Frank Pallone (D-NJ).
E&C Website: https://energycommerce.house.gov
E&C Twitter: https://twitter.com/HouseCommerce
E&C Facebook: https://www.facebook.com/energyandcommerce/
E&C Instagram: https://www.instagram.com/energyandcommerce/
good morning everyone today this
committee will continue our work to
ensure America Remains the world leader
in biomedical Innovation we've
previously heard testimony on many
examples of regulatory and reimbursement
challenges that are stifling Innovation
and delaying patient access to care
unfortunately the FDA is doubling down
on this troubling pattern by failing to
account for the important role
Laboratory Testing plays in this country
patients doctors and caregivers rely on
diagnostic test to detect guide
treatment decisions and monitor a host
of medical conditions and diseases some
of these tests are made in the form of
kits by conventional manufacturers for
the use by other entities such as
Laboratories healthc care practitioners
or even
patients other tests known as laboratory
developed tests or ldts are designed
manufactured and used within a single
laboratory while conventional
manufacturers certainly serve an
important role ldts fill in the gap for
indicators that have a smaller patient
population such as rare diseases
particularly cancers and certain
pediatric conditions where large scale
commercial manufacturing and
distribution do not make sense instead
of capitalizing on advancements in
Precision medicine and exciting genetic
Technologies to help patients the FDA
has proposed dramatically increasing the
regulatory burden on a subset of
diagnostic tests specifically
ldts these regulations extend far beyond
any of the legislative proposals that
Congress has considered under the
proposed rule Laboratories will incur
significant cost to come into Compliance
New administrative and clerical burdens
along with oppressive submission fees
will be a substantial drain on a lab's
limited
resources take for example a lab that
offers a thousand laboratory developed
tests by fda's estimate 50% of existing
ldts will require pre-market submissions
that alone translates to hundreds of
millions of dollars not even accounting
for ongoing changes in maintenance
moreover for a phase out period over
four years this lab will need to submit
250 test a year or one per working day
something that is likely impossible for
the lab to do and for FDA to review in a
timely
manner according to a recent survey of
over 500 Clinical Laboratory respondents
only 3% of the labs believe that they
will have the financial resources to pay
user fees for the overwhelming number of
labs without the financial resources
they will have to stop performing tests
severely limiting access for some of our
most vulnerable patient
populations and is preliminary
preliminary regulatory impact analysis
the FDA estimates estimates that there's
880,000 ldts currently on the market and
nearly 8,000 new ldts per year that
would be affected by the rule by
comparison the agency approved a little
over 3,000 pre-market submissions in
2022 as currently written the rule would
take FDA years to Simply review the
tests that already exist on the market
but what does this all really
mean given that the FDA is already
struggling to keep up with Innovation
and what it currently regulates this
undertaking would mean fewer diagn
diagnosis
diagnosises higher cost and delays in
care for
patients who can't afford to wait for
the FDA to approve a test they need to
finally figure out what is wrong and the
path to getting well their lives depend
on it I know members of this committee
hold a variety of positions on the need
for regulating ldts and the manner in
which Congress should do so I would hope
that we would all agree that this rule
is on the wrong path I look forward to
hearing more from our Witnesses about
legislative alternatives to this
stifling administrative action thank you
and I yield back thank you the chair
